MUMBAI (Reuters) - Generics drugmaker Alkem Laboratories received orders worth 44 times the number of available shares for its 13.5 billion rupee ($202.37 million) initial public offering, according to exchange data.
Alkem had received orders for about 401 million shares as of 5 p.m., well above the 9.1 million shares on offer, according to data from the National Stock Exchange and BSE Ltd. Bookbuilding will close later on Thursday.
Qualified institutional investors were the most active bidders, having placed orders worth about 57.2 times the number of shares slotted.
Meanwhile, Dr. Lal Pathlabs' 6.3 billion rupees ($94.44 million) IPO, whose bookbuilding also ends on Thursday, was subscribed about 33 times the number of available shares.
($1 = 66.7100 rupees)
(Reporting by Karen Rebelo in Mumbai; Editing by Biju Dwarakanath)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app